Ignite Creation Date:
2024-10-26 @ 3:35 PM
Last Modification Date:
2024-10-26 @ 3:35 PM
Study NCT ID:
NCT06515314
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-07-17
Brief Title:
HRYZ-T102 TCR-T Cell for AFP Positive Advanced HCC and Other Solid Tumors
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Phase 1 Single-arm Open-label Dose-escalation Study of AFP Specific T Cell Receptor Transduced T Cells InjectionHRYZ-T102in Patients With AFP Positive Advanced Hepatocellular Carcinoma and Other Solid Tumors
Status:
RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a single arm open-label dose escalation clinical study to evaluate the safety and efficacy of HRYZ-T102 TCR-T Cell in patients with AFP positive advanced hepatocellular carcinoma and other solid tumors refractory to prior systematic treatments
Detailed Description:
This study plans to enroll 12-24 patients to assess the safety of HRYZ-T102 Subjects who meet the eligibility criteria will receive a single dose of HRYZ-T102 injection The patient will be followed up 24 months
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None